Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011, Article ID 404916, 7 pages
http://dx.doi.org/10.4061/2011/404916
Clinical Study

Selective Internal Radiation Therapy for Gastrointestinal Neuroendocrine Tumour Liver Metastases: A New and Effective Modality for Treatment

Wakefield Gastroenterology Centre and University of Otago, Private Bag 7909, Wellington 6242, New Zealand

Received 15 June 2011; Revised 3 September 2011; Accepted 3 September 2011

Academic Editor: Dan Granberg

Copyright © 2011 Harshal Rajekar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. D. O'Toole and P. Ruszniewski, “Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours,” Best Practice and Research: Clinical Gastroenterology, vol. 19, no. 4, pp. 585–594, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M. Van Essen, E. P. Krenning, B. L. R. Kam, M. De Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide-receptor radionuclide therapy for endocrine tumors,” Nature Reviews Endocrinology, vol. 5, no. 7, pp. 382–393, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. W. Y. Lau, S. Ho, T. W. T. Leung et al., “Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres,” International Journal of Radiation Oncology Biology Physics, vol. 40, no. 3, pp. 583–592, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Gray, G. Van Hazel, M. Buck, G. Paton, M. Burton, and J. Anderson, “Treatment of colorectal liver metastases with SIR-spheres plus chemotherapy,” GI Cancer, vol. 3, no. 4, pp. 249–257, 2000. View at Google Scholar · View at Scopus
  6. R. S. Stubbs, R. J. Cannan, and A. W. Mitchell, “Selective internal radiation therapy with 90Yttrium microspheres for extensive colorectal liver metastases,” Journal of Gastrointestinal Surgery, vol. 5, no. 3, pp. 294–302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. King, R. Quinn, D. M. Glenn et al., “Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases,” Cancer, vol. 113, no. 5, pp. 921–929, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. S. Kennedy, W. A. Dezarn, P. McNeillie et al., “Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients,” American Journal of Clinical Oncology, vol. 31, no. 3, pp. 271–279, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. T. W. Leung, W. Y. Lau, S. K. Ho et al., “Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors,” International Journal of Radiation Oncology Biology Physics, vol. 33, no. 4, pp. 919–924, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. J. D. Godwin, “Carcinoid tumors. An analysis of 2837 cases,” Cancer, vol. 36, no. 2, pp. 560–569, 1975. View at Google Scholar · View at Scopus
  11. J. F. Sweeney and A. S. Rosemurgy, “Carcinoid tumors of the gut,” Cancer Control, vol. 4, no. 1, pp. 18–24, 1997. View at Google Scholar · View at Scopus
  12. B. Eriksson and K. Öberg, “Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook,” Annals of Oncology, vol. 10, supplement 2, pp. S31–S38, 1999. View at Google Scholar
  13. I. M. Modlin, M. Pavel, M. Kidd, and B. I. Gustafsson, “Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 2, pp. 169–188, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Rinke, H. H. Müller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. Ricci, A. Antonuzzo, L. Galli et al., “Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors,” American Journal of Clinical Oncology, vol. 23, no. 4, pp. 412–415, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Eriksson, J. Renstrup, H. Imam, and K. Öberg, “High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects,” Annals of Oncology, vol. 8, no. 10, pp. 1041–1044, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Loewe, M. Schindl, M. Cejna, B. Niederle, J. Lammer, and S. Thurnher, “Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results,” American Journal of Roentgenology, vol. 180, no. 5, pp. 1379–1384, 2003. View at Google Scholar · View at Scopus
  18. D. C. Madoff, S. Gupta, K. Ahrar, R. Murthy, and J. C. Yao, “Update on the management of neuroendocrine hepatic metastases,” Journal of Vascular and Interventional Radiology, vol. 17, no. 8, pp. 1235–1250, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. C. G. Moertel, C. M. Johnson, M. A. McKusick et al., “The management of patients with advanced carcinoid tumors and islet cell carcinomas,” Annals of Internal Medicine, vol. 120, no. 4, pp. 302–309, 1994. View at Google Scholar · View at Scopus
  20. G. A. Kaltsas, J. J. Mukherjee, A. Isidori et al., “Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil,” Clinical Endocrinology, vol. 57, no. 2, pp. 169–183, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Oberg and B. Eriksson, “The role of interferons in the management of carcinoid tumours,” British Journal of Haematology, vol. 79, no. 1, supplement, pp. 74–77, 1991. View at Google Scholar · View at Scopus
  22. K. Stuart, D. E. Levy, T. Anderson et al., “Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the eastern cooperative oncology group,” Investigational New Drugs, vol. 22, no. 1, pp. 75–81, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Sun, S. Lipsitz, P. Catalano, J. A. Mailliard, and D. G. Haller, “Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 4897–4904, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. J. G. Touzios, J. M. Kiely, S. C. Pitt et al., “Neuroendocrine hepatic metastases: does aggressive management improve survival?” Annals of Surgery, vol. 241, no. 5, pp. 776–785, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. K. E. Öberg, J. Reubi, D. J. Kwekkeboom, and E. P. Krenning, “Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy,” Gastroenterology, vol. 139, no. 3, pp. 742–e1, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. J. Kwekkeboom, J. Mueller-Brand, G. Paganelli et al., “Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs,” Journal of Nuclear Medicine, vol. 46, no. 1, 2005. View at Google Scholar
  27. D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker et al., “Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2754–2762, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. M. Van Essen, E. P. Krenning, M. De Jong, R. Valkema, and D. J. Kwekkeboom, “Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours,” Acta Oncologica, vol. 46, no. 6, pp. 723–734, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. C. Waldherr, M. Pless, H. R. Maecke, A. Haldemann, and J. Mueller-Brand, “The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study,” Annals of Oncology, vol. 12, no. 7, pp. 941–945, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. E. T. Janson, B. Eriksson, K. Öberg et al., “Treatment with high dose [111In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors—evaluation of therapeutic and toxic effects,” Acta Oncologica, vol. 38, no. 3, pp. 373–377, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. B. I. Carr, “Hepatic arterial 90Yttrium glass microspheres (therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients,” Liver Transplantation, vol. 10, no. 2, supplement 1, pp. S107–S110, 2004. View at Google Scholar
  32. B. N. Gray, J. E. Anderson, M. A. Burton et al., “Regression of liver metastases following treatment with yttrium-90 microspheres,” Australian and New Zealand Journal of Surgery, vol. 62, no. 2, pp. 105–110, 1992. View at Google Scholar · View at Scopus
  33. R. S. Stubbs, I. O'Brien, and M. M. Correia, “Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients,” ANZ Journal of Surgery, vol. 76, no. 8, pp. 696–703, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. S. Kennedy, D. Coldwell, C. Nutting et al., “Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 2, pp. 412–425, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. R. Murthy, R. Nunez, J. Szklaruk et al., “Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications,” Radiographics, vol. 25, pp. S41–S55, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. G. Pöpperl, T. Helmberger, W. Münzing, R. Schmid, T. F. Jacobs, and K. Tatsch, “Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors,” Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 2, pp. 200–208, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. R. Salem and K. G. Thurston, “Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies—part 3: comprehensive literature review and future direction,” Journal of Vascular and Interventional Radiology, vol. 17, no. 10, pp. 1571–1593, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Ho, W. Y. Lau, T. W. T. Leung et al., “Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours,” European Journal of Nuclear Medicine, vol. 23, no. 8, pp. 947–952, 1996. View at Google Scholar · View at Scopus
  39. M. A. Burton, B. N. Gray, P. F. Klemp, D. K. Kelleher, and N. Hardy, “Selective internal radiation therapy: distribution of radiation in the liver,” European Journal of Cancer and Clinical Oncology, vol. 25, no. 10, pp. 1487–1491, 1989. View at Google Scholar · View at Scopus
  40. M. Sarfaraz, A. S. Kennedy, Z. J. Cao et al., “Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors,” Medical Physics, vol. 30, no. 2, pp. 199–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Boppudi, S. K. Wickremesekera, M. Nowitz, and R. Stubbs, “Evaluation of the role of CT in the assessment of response to selective internal radiation therapy in patients with colorectal liver metastases,” Australasian Radiology, vol. 50, no. 6, pp. 570–577, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. N. Arslan, M. Emi, E. Alagöz et al., “Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center,” Vojnosanitetski Pregled, vol. 68, no. 4, pp. 341–348, 2011. View at Publisher · View at Google Scholar